Keyphrases
Pediatric Patients
100%
Crohn's Disease
100%
Adalimumab
100%
Complete Response
23%
Partial Response
23%
Adverse Events
15%
Serious Adverse Events
15%
Infliximab
15%
No Response
15%
Tumor Necrosis Factor-α
7%
Institutional Review Board
7%
Adverse Effects
7%
Treatment Course
7%
Lost to Follow-up
7%
Retrospective Chart Review
7%
Pediatric Population
7%
Clinical Response
7%
Adult Patients
7%
Nausea
7%
Duration of Therapy
7%
Therapy Initiation
7%
Single Institution
7%
Patient Charts
7%
Need for Surgery
7%
Anaphylaxis
7%
Serious Infection
7%
Optimal Dosing
7%
Loading Dose
7%
Response-adapted
7%
Abdominal Pain
7%
Cleveland Clinic
7%
Extent of Disease
7%
Age at Diagnosis
7%
Concurrent Medications
7%
Age at Initiation
7%
Fistula Closure
7%
Fistulizing Disease
7%
Temporary Closure
7%
Medicine and Dentistry
Pediatrics Patient
100%
Adalimumab
100%
Patient with Crohn's Disease
100%
Adverse Event
38%
Diseases
15%
Infliximab
15%
Side Effect
7%
Treatment Duration
7%
Drug Therapy
7%
Tumor Necrosis Factor
7%
Crohn's Disease
7%
Nausea
7%
Infection
7%
Abdominal Pain
7%
Anaphylaxis
7%
Fistula
7%
Loading Drug Dose
7%
Sex Diagnosis
7%
Pediatrics
7%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
100%
Adalimumab
100%
Adverse Event
38%
Disease
15%
Infliximab
15%
Tumor Necrosis Factor
7%
Infection
7%
Side Effect
7%
Abdominal Pain
7%
Nausea
7%
Anaphylaxis
7%
Fistula
7%
Immunology and Microbiology
Adalimumab
100%
Crohn's Disease
100%
Infliximab
15%
Tumor Necrosis Factor Alpha
7%
Loading Drug Dose
7%
Anaphylaxis
7%